9 completed, 2 active not recruiting, 1 not yet recruiting, 1 terminated. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 9, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow FG-4592: new trials by email Literature Review of FG-4592 trials Research Report on FG-4592
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery. Roxadustat - Perioperative Anemia | Phase 3 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 158 | 2024-11-10 | 2025-01-13 |
| A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease Roxadustat - Chronic Kidney Disease, Renal Anemia | Phase 3 | Active not recruiting | Astellas Pharma Global Development, Inc. | 98 | 2024-01-16 | 2026-10-13 |
| Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD Roxadustat - Anemia Associated With Chronic Kidney Disease | Phase 3 | Withdrawn | Kyntra Bio | 2022-05-23 | 2022-07-05 | |
| A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies SEPO®, Roxadustat - Chemotherapy Induced Anemia | Phase 3 | Completed | Kyntra Bio | 159 | 2022-03-16 | 2023-06-06 |
| Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) FG-4592, Placebo - Anemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Completed | Kyntra Bio | 43 | 2018-06-06 | 2023-05-03 |
| Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden Roxadustat, Placebo - Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia | Phase 3 | Terminated | Kyntra Bio | 184 | 2018-01-29 | 2024-08-01 |
| FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease FG-4592, Epoetin Alfa - Anemia | Phase 3 | Completed | Kyntra Bio | 305 | 2015-12-01 | 2017-08-24 |
| FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis FG-4592, Placebo - Anemia | Phase 3 | Completed | Kyntra Bio | 154 | 2015-12-01 | 2017-08-24 |
| Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Epoetin Alfa, Roxadustat - CKD Anemia in Stable Dialysis Patients | Phase 3 | Completed | Kyntra Bio | 741 | 2015-01-15 | 2021-10-29 |
| Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Roxadustat, Epoetin alfa, Darbepoetin alfa - Anemia, End Stage Renal Disease (ESRD) | Phase 3 | Completed | Astellas Pharma Europe B.V. | 838 | 2014-11-21 | 2024-11-27 |
| Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants Roxadustat, Epoetin Alfa - Anemia in Incident Dialysis Patients | Phase 3 | Completed | Kyntra Bio | 1043 | 2014-02-11 | 2021-10-01 |
| Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis Roxadustat, Placebo - Anemia in Chronic Kidney Disease in Non-dialysis Patients | Phase 3 | Completed | Astellas Pharma Europe B.V. | 594 | 2013-09-03 | 2024-11-14 |
| A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis Roxadustat, Placebo - CKD Anemia | Phase 3 | Completed | Kyntra Bio | 922 | 2012-11-05 | 2021-10-01 |
Anemia (13) · Renal Insufficiency, Chronic (9) · Kidney Failure, Chronic (5) · Myelodysplastic Syndromes (3)
Kyntra Bio (10) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Global Development, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (5) · Poland (5) · United States (5) · Belgium (4) · Italy (4) · Romania (4) · Russia (4) · Spain (4) · United Kingdom (4) · Bulgaria (3) · Colombia (3) · Germany (3) · South Korea (3) · Turkey (Türkiye) (3) · Argentina (2)
Charles Bradley, PhD (1) · Mark Eisner, MD, MPH (1) · Meraf Eyassu (1) · Min Yan, MD, PhD (1)
PMID 36005278, PMID 38363466, PMID 34362786, PMID 36749544, PMID 31340089, PMID 31340116, PMID 33732977, PMID 34724251, PMID 36710399, PMID 39353163